Clinical Trial Update: Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis [Phase 4]

View source ↗

Summary

Phase 4 trial comparing paricalcitol (Zemplar) and calcitriol (Calcijex) in adults with end-stage kidney disease on hemodialysis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Kidney Disease

Drugs mentioned

• Calcijex (calcitriol)
• Zemplar (Paricalcitol)

Snippet

Sponsor: Abbott | Conditions: End-Stage Kidney Disease | Phase 4 | Status: TERMINATED